Aura is a drug development company using synthetic biology to develop novel cancer drugs.
Aura Biosciences is a drug development oncology company . The technology is based on synthetic viruses that can target drugs to tumors with a unique mechanism of action. We have a solid IP portfolio, with an exclusive license from the National Cancer Institute. Our lead candidate is in late pre-clinical development for a rare cancer indication, ocular melanoma. We have key support from seasoned pharma investors including Henri Termeer.